Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population
Abstract
Introduction: CYP2C9 metabolizes approximately 15% of the prescribed drugs. Its gene has alleles whose frequencies differ between ethnic groups and populations. The alleles CYP2C9*2 and CYP2C9*3 account for an enzyme with decreased activity and their frequencies have not been determined in the Peruvian mestizo population.
Objective: To characterize the frequencies of the allelic variants *2 (rs1799853) and *3 (rs1057910) of CYP2C9 gen in the Peruvian mestizo population from Lima, Tacna y Junín.
Materials and methods: We conducted an observational, prospective cross-sectional study with non-probabilistic, by convenience, and incidental sampling. We included 218 subjects according to the inclusion and exclusion criteria, all of whom had signed the informed consent. We obtained the genomic DNA from oral mucosa swab. For the detection of the CYP2C9*2 and CYP2C9*3 genotypes, we used real-time-polymerase chain reaction with TaqMan® probes.
Results: The genotyping revealed that CYP2C9*2 and CYP2C9*3 variants have low frequencies (0.046 and 0.062, respectively). The frequency of intermediate metabolizers was 15.13% (CYP2C9*1/*2: 5.96%; CYP2C9*1/*3: 9.17%) and that of slow metabolizers was 3.22% (CYP2C9*2/*2: 1.38%; CYP2C9*3/*3: 1.38%; CYP2C9*2/*3: 0.46%).
Conclusions: It was possible to determine the genotypic and allelic frequencies for the variants *2 and *3 of the CYP2C9 gene in a non-probabilistic sample of the Peruvian mestizo population. The frequencies obtained (0.046 and 0.062, respectively) corresponded to those expected for a South American mestizo population with Amerindian, European, African and Asian ancestry.
Downloads
References
Miranda C, Roco A, Garay J, Squicciarini V, Tamayo E, Agúndez J, et al. Determinación del polimorfismo de CYP2C9*2 y su relación con la farmacocinética de acenocumarol en voluntarios sanos. Rev Chil Cardiol. 2011;30:218-24. https://doi.org/10.4067/S0718-85602011000300005
Cotuá-Urzola J, Morales-Ortiz A, Delgado-Niño M, Muñoz-Jáuregui A, Quiñones-Sepúlveda L, Alvarado-Yarasca A, et al. Determinación del nivel de dosis del ácido valproico e influencia de los fármacos inductores y no inductores enzimáticos en pacientes voluntarios de la ciudad de Mérida, Venezuela. Horiz Med. 2017;17:29-33. https://doi.org/10.24265/horizmed.2017.v17n3.05
Ortiz L, Tabak R. Farmacogenómica en la práctica clínica. Rev Med Clin Condes. 2012;23:616-20. https://doi.org/10.1016/S0716-8640(12)70356-5
Céspedes-Garro C, Fricke-Galindo I, Naranjo M, Rodrigues-Soares F, Fariñas H, de Andrés F, et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin. Drug Metab. Toxicol. 2015;11:1893-905. https://doi.org/10.1517/17425255.2015.1111871
Saldaña-Cruz A, Sánchez-Corona J, Márquez-de Santiago D, García-Zapién A, Flores-Martínez S. Farmacogenética y metabolismo de fármacos antiepilépticos: implicación de variantes genéticas en citocromos P450. Rev Neurol. 2013;56:471-9.
Mukai Y, Narita M, Akiyama E, Ohashi K, Horiuchi Y, Kato Y, et al. Co-administration of fluvastatin and CYP3A4 and cyp2c8 inhibitors may increase the exposure to fluvastatin in carriers of CYP2C9 genetic variants. Biol Pharm Bull. 2017;40:1078-85. https://doi.org/10.1248/bpb.b17-00150
Balestrini S, Sisodiya S. Pharmacogenomics in epilepsy. Neurosci Lett. 2018;667:27-39. https://doi.org/10.1016/j.neulet.2017.01.014
Quiñones L, Roco A, Cayún J, Escalante P, Miranda C, Varela N, et al. Farmacogenómica como herramienta fundamental para la medicina personalizada: aplicaciones en la práctica clínica. Rev Med Chile. 2017;145:483-500. https://doi.org/10.4067/S0034-98872017000400009
Caudle K, Rettie A, Whirl-Carrillo M, Smith L, Mintzer S, Lee M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96:542-8. https://doi.org/10.1038/clpt.2014
Grover S, Gourie-Devi M, Baghel R, Sharma S, Bala K, Gupta M, et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010;11:927-41. https://doi.org/10.2217/pgs.10.62
Claudio-Campos K, Labastida A, Ramos A, Gaedigk A, Renta-Torres J, Padilla D, et al. Warfarin anticoagulation therapy in Caribbean Hispanics of Puerto Rico: A candidate gene association study. Front Pharmacol. 2017;8:1-17. https://doi.org/10.3389/fphar.2017.00347
Fricke-Galindo I, Jung-Cook H, Llerena A, López-López M. Farmacogenética de reacciones adversas a fármacos antiepilépticos. Rev Neurol. 2018;33:165-76. https://doi.org/10.1016/j.nrl.2015.03.005
Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011;18:1159-64. https://doi.org/10.1111/j.1468-1331.2011.03361.x
Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013;13:359-61. https://doi.org/10.1038/tpj.2012.19
Babu K, Ramesh V, Samidorai A, Charles C. Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: A case report. J Pharm Bioallied Sci. 2013;5:237-9. https://doi.org/10.4103/ 0975-7406.116828
Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents. Int J Cardiol. 2013:163:79-86. https://doi.org/10.1016/j.ijcard.2012.09.075
García-Lagunar M, Consuegra-Sánchez L, Conesa- Zamora P, Ruiz-Cosano J, Soria-Arcos F, García de Guadiana L, et al. Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome. Anatol J Cardiol. 2017;17:303-12. https://doi.org/10.14744/AnatolJCardiol.2016.7390
Wang Y, Yi XD, Lu BL. Influence of CYP2C9 and COX-2 genetic polymorphisms on clinical efficacy of non-steroidal anti-inflammatory drugs in treatment of ankylosing spondylitis. Med Sci Monit. 2017;23:1775-82. https://doi.org/10.12659/MSM.900271
Homburger J, Moreno-Estrada A, Gignoux C, Nelson D, Sánchez E, Ortiz-Tello P, et al. Genomic insights into the ancestry and demographic history of South America. PLoS Genet. 2015;11:1-26. https://doi.org/10.1371/journal.pgen.1005602
National Geographic. Reference Populations-Geno 2.0 Next Generation-2018 Fecha de consulta: 6 de mayo de 2018. Disponible en: https://genographic.nationalgeographic.com/reference-populations-next-gen/
Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sánchez M, Jaramillo C, Arias W, et al. Admixture in Latin America: Geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet. 2014;10:1-13. https://doi.org/10.1371/journal.pgen.1004572
Moyano L. Epidemiología de la epilepsia en el Perú: Neurocisticercosis como causa de epilepsia secundaria en la región norte del Perú. Tesis. Human health and pathology. Université de Limoges; 2016. Español (NNT: 2016LIMO0135). https://tel.archives-ouvertes.fr/tel-01544029
Daly A, Rettie A, Fowler D, Miners J. Review pharmacogenomics of CYP2C9: Functional and clinical considerations. J Pers Med. 2018;8:1-31. https://doi.org/10.3390/jpm8010001
Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19
genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402-8. https://doi.org/10.1038/clpt.2013.2
Nakai K, Habano W, Nakai K, Fukushima N, Suwabe A, Moriya S, et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci. 2005;78:107-11. https://doi.org/10.1016/j.lfs.2005.04.049
Asociación Médica Mundial. Declaración de Helsinki. Principios éticos para las investigaciones médicas en seres humanos, 2017.Fecha de consulta: 22 de marzo de 2018. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-ammprincipios-eticos-para-las investigaciones-medicas-en-seres-humanos/
Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. Eur J Clin Pharmacol. 2005;61:179-84. https://doi.org/10.1007/ s00228-004-0890-5
Roco A, Quiñones L, Agúndez JA, García-Martín E, Squicciarini V, Miranda C, et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: Comparison with Caucasian and Asian populations. Front Genet. 2012;3:1-9. https://doi.org/10.3 389/fgene.2012.00229
Soares RA, Santos PC, Machado-Coelho GL, Marques do Nascimento R, Mill JG, Krieger JE, et al. CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry. Genet Test Mol Biomarkers. 2012;16:957-63. https://doi.org/10.1089/gtmb.2012.0019
Sánchez-Díaz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibáñez L, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J. 2009;9:306-10. https://doi.org/10.1038/tpj.2009.16
Vicente J, Gonzáles-Andrade F, Soriano A, Fanlo A, Martínez-Jarreta B, Sinués B. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: A comparative study. Mol Biol Rep. 2014;41:1267-72. https://doi.org/10.1007/s11033-013-2971-y
Some similar items:
- Carlos P. Padilla, Uriel Alvarado, Gladis Ventura, Deysi Luna-Caipo, Marcial Suárez, José R. Tuñoque, Nancy Ruelas-Llerena, Luis A. Fachín, Alina Huiza, Lizandro Gonzáles, Julio César Carranza, Gustavo Adolfo Vallejo, Gustavo Adolfo Vallejo, Abraham G. Cáceres, Abraham G. Cáceres, Identifying Trypanosoma cruzi discreet typing units in triatomines collected in different natural regions of Perú , Biomedica: Vol. 37 No. Sup. 2 (2017): Suplemento 2, Entomología médica, 2017
- Liliana Franco-Hincapié, Constanza Elena Duque, María Victoria Parra, Natalia Gallego, Alberto Villegas, Andrés Ruiz-Linares, Gabriel Bedoya, Association between polymorphism in uncoupling proteins and type 2 diabetes in a northwestern Colombian population , Biomedica: Vol. 29 No. 1 (2009)
- Alberto Gómez, Sandra J. Ávila, Ignacio Briceño, Correlation analysis of surnames and Y-chromosome genetic heritage in 3 provinces of southwestern Colombia , Biomedica: Vol. 28 No. 3 (2008)
- Libia M. Rodríguez, Mabel C. Giraldo, Natalia García, Laura Velásquez, Sara C. París, Cristiam M. Álvarez, Luis F. García, Human leucocyte antigen gene (HLA-A, HLA-B, HLA-DRB1) frequencies in deceased organ donors , Biomedica: Vol. 27 No. 4 (2007)
- Carlos Isaza, Leonardo Beltrán, Julieta Henao, Gloria Porras, Alfredo Pinzón, Álvaro Vallejos, Jorge Machado, Genetic and bioenvironmental factors associated with warfarin response in Colombian patients , Biomedica: Vol. 30 No. 3 (2010)
- Marylin Hidalgo, Claudia Santos, Carolina Duarte, Elizabeth Castañeda, Clara Inés Agudelo, Increase in erythromycin-resistant Streptococcus pneumoniae in Colombia, 1994-2008 , Biomedica: Vol. 31 No. 1 (2011)
- Lucero Rengifo, Duverney Gaviria, Herman Serrano, APOE gene polymorphisms associated with Down syndrome in Colombian populations , Biomedica: Vol. 32 No. 2 (2012)
- Raquel E. Ocazionez-Jiménez, Ayda Susana Ortiz-Báez, Sergio Yebrail Gómez-Rangel, Daniel R. Miranda-Esquivel, Dengue virus serotype 1 (DENV-1) from Colombia: its contribution to dengue occurrence in Santander , Biomedica: Vol. 33 (2013): Suplemento 1, Fiebres hemorrágicas
- Iván Moreno, Luis Quiñones, Johanna Catalán, Carla Miranda, Angela Roco, Jaime Sasso, Evelyn Tamayo, Dante Cáceres, Andrei N. Tchernitchin, Leonardo Gaete, Iván Saavedra, Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study , Biomedica: Vol. 32 No. 4 (2012)
- Elsa Villarreal, Antonio Bermúdez, Polymorphisms of APO-E in Colombian women with osteoporosis: correlation with clinical and social risk variables. , Biomedica: Vol. 24 No. 1 (2004)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
